Vessel maneuvers: Vaccine targets tumor vasculature

Nature Medicine

Volumn 8, Issue 12, 2002, Pages 1352-1353

  O'Reilly, Michael S ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; DNA VACCINE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANIMAL MODEL; CANCER IMMUNOTHERAPY; DRUG TARGETING; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; T LYMPHOCYTE; TUMOR BLOOD FLOW; TUMOR CELL; TUMOR IMMUNOLOGY; VACCINATION;

ANIMALS; MICE; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; VACCINES, DNA; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

ANIMALIA;

EID: 0036918335     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1202-1352     Document Type: Short Survey

References (11)

1. Forkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med. 1, 27-31 (1995).
2. Boehm, T., Folkman, J., Browder, T. & O'Reilly, M.S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390, 404-407 (1997).
3. Niethammer, A.G. et al. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nature Med. 8, 1369-1375 (2002).
4. Alon, T. et al. VEGF acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nature Med. 1, 1024-1028 (1995).
5. O'Reilly, M.S. & Fidler, I.J. The development of antiangiogenic agents for the clinic, in Progress in Oncology 2002 (eds. DeVita, V.T., Hellman, S. & Rosenberg, S.A.) 129-157(Jones and Bartlett Publishers, Sudbury, 2002).
6. Kuenen, B.C. et al. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J. Clin. Oncol. 20, 1657-1667 (2002).
7. Yu, J.L., Rak, J.W., Coomber, B.L., Hicklin, D.J. & Kerbel, R.S. Effect of p53 status on tumor response to antiangiogenic therapy. Science 295, 1526-1528 (2002).
8. Relf, M. et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet-derived endothelial cell growth factor, placenta growth factor and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 57, 963-969 (1997).
9. Kaban, L.B. et al. Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon α-2a. Pediatrics 103, 1145-1149 (1999).
10. O'Reilly, M.S., Holmgren, L., Chen, C. & Folkman, J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Med. 2, 689-692 (1996).
11. Kerbel, R. & Folkman, J. Clinical translation of angiogenesis inhibitors. Nature Rev. Cancer 2, 727-739 (2002).